EHA 18: Rituximab for b-cell lymphoma and EHA overview

Andrew Davies: EHA 2020 lymphoma highlightsПодробнее

Martin Dreyling | EHA 2018 | Overview of EHA presentations in indolent lymphomaПодробнее

CAR-T is Feasible in B-Cell Lymphoma Patients Over 80 Years Old | Julio Chavez, MD | EHA 2024Подробнее

Exciting advancements in NHL from EHA 2024Подробнее

Ulrich Jager | EHA 2018 | Potential causes of aggressive B-cell lymphomas under JAK1/2 inhibitionПодробнее

Genmab and AbbVie Present New Epcoritamab Data at EHA 2023Подробнее

John Kuruvilla | EHA 18 | SADAL clinical trial in DLBCLПодробнее

Golcadomide ± Rituximab in R/R Follicular Lymphoma: Phase 1/2 Study | Julio Chavez, MD | EHA 2024Подробнее

What’s New In Diffuse Large B-Cell LymphomaUpdates from ASCO 2024 & the EHA Hybrid CongressПодробнее

EHA 2016 Christian Gisselbrecht InterviewПодробнее

Aggressive lymphoma updates - with Dr Michael Dickinson. EHA 2020Подробнее

EHA 2023 T-cell lymphoma highlightsПодробнее

Molecular subtypes in diffuse large B-cell lymphomaПодробнее

The unmet need in DLBCLПодробнее

Indolent lymphoma updates - with Professor John Seymour. EHA 2020Подробнее

The safety and efficacy of CC-95251 in combination with rituximab for R/R NHLПодробнее

Town Hall on ASCO, EHA & ICML - LymphomasПодробнее

The importance of diagnosing DLBCL on a molecular level and how it will improve treatmentПодробнее